The Global Intravenous Immunoglobulin Market is likely to witness considerable growth driven by recent molecular advancements. According to a report published by Fortune Business Insights, titled “Intravenous Immunoglobulin Market Size, Share & Industry Analysis By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Regional Forecast, 2018 – 2025,” the was valued at USD 9,787.6 Million in 2017 and is projected to reach USD 15,789.1 Million by 2025 exhibiting a CAGR of 6.2% in the forecast period (2018-2025).
Intravenous immunoglobulin is a blood product prepared from the serum of a particular range. It is mostly used for treatment of patients with major antibody deficiencies. They are categorized as glycoprotein molecules manufactured by plasma or white blood cells (WBC). These products are used to enhance the immune system by binding specific antigens such as bacteria and virus. As a result, they cater to patients with a weaker or exposed immune system.
Intravenous immunoglobulins are the type of drugs that are directly administered to the veins through syringes. The intravenous route is preferred n critical and bed-ridden patients, that have a lesser effect through oral or other modes. The proven efficiency of these drugs will lead to high product adoption across the world.
Growing Regulatory Approvals Will Open the Doors for Rapid Growth
The high demand for immunoglobulins has given rise to an increase in the overall investments in the development of these products across the world. Increasing investments have led to a subsequent rise in the number of clinical trials. Encouraged by successful clinical trials and excellent results, the regulatory bodies are actively approving several new products. Increasing regulatory clearances will have a direct impact on the growth of the global market. A few of the major drug approvals of recent times are summarized below.
- AMDA Biologics’ Bivigam was cleared by the Food and Drug Administration in 2019. The company is likely to begin commercialization and sale of its product in the coming years.
- Asceniv, another immunoglobulin by proposed by ADMA, was approved by the FDA. The product was manufactured, with focus on severe immunodeficiency cases.
Get PDF Brochure of this Report@ https://www.fortunebusinessinsights.com/enquiry/sample/intravenous-immunoglobulins-market-100593
Some of the leading companies that are operating in the Intravenous Immunoglobulin Market are:
- Shire (Takeda Pharmaceutical Company Limited)
- CSL Behring
- Grifols, S.A.
- Kedrion S.p.A
- Bio Products Laboratory Ltd.
- Biotest AG
- China Biologic Products Holdings, Inc.
- LFB SA
- Shanghai RAAS Blood Products Co., Ltd.
Increasing Cases of Severe Immunodeficiency Have Fuelled Product Demand
The increasing number of immunodeficiency patients, coupled with the impact of these products in treatment and diagnosis of related patients, will favor the growth of the market in the coming years. Recent molecular advancements have enabled higher product efficiencies. The demand for intravenous immunoglobulin is primarily driven by its cost-effective nature and excellent clinical results.
This mode of treatment is normally the first preference for patients with severe immune disorders. It is observed that the number of patients with immune disorders is the highest in North America. Moreover, there is a high product adoption and a high emphasis on the development of intravenous immunoglobulin in this region. The market North America was valued at USD 5,587.4 Mn in 2017 and is likely to witness rapid growth in the coming years.
Order Full Report@ https://www.fortunebusinessinsights.com/checkout-page/100593
By End User
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245